- Home
- MODD vs GTBP Comparison
MODD vs GTBP Comparison
Compare MODD & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MODD | GTBP |
|---|---|---|
| Founded | 1998 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2M | 13.0M |
| IPO Year | 2019 | 2016 |
Fundamental Metrics
Financial Performance| Metric | MODD | GTBP |
|---|---|---|
| Price | $3.40 | $0.28 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 347.6K | ★ 366.9K |
| Earning Date | 02-17-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.75 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $0.26 |
| 52 Week High | $6.16 | $1.37 |
Technical Indicators
Market Signals| Indicator | MODD | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 53.20 | 39.21 |
| Support Level | $3.13 | $0.27 |
| Resistance Level | $5.84 | $0.49 |
| Average True Range (ATR) | 0.53 | 0.02 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 70.26 | 18.51 |
Price Performance
Historical ComparisonAbout MODD Modular Medical Inc.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, marketing and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.